Harmony Biosciences Holdings, Inc. (HRMY) — closed signal from October 11, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 9, 2026.
Predicted vs. what happened
What happened
Reached its target in 44 days.
The thesis — published October 11, 2025
- Clarify the setup - Explain rebound odds - Note news and analyst view - Outline timing and risk After a hard drop, signs show buyers returning. The core business still helps despite a failed study. News focused on the miss, yet a well-known firm kept a Buy (with a lower target), showing support. Adding near the range aims at a 0-3 month reset as attention shifts back to the main drugs.
Primary drivers
- Price is beaten down, and signs show buyers returning again now.
- Healthy core business helps limit downside while plans reset near term.
- Analyst kept a Buy rating after the trial miss, showing support.
- Short-term price snapback possible as attention returns to main drugs.
How it played out
HRMY: target reached in 44 days
Lyra published HRMY at 26.54 on 2025-10-11 with expected growth of 32% and a target of 35.03. The thesis pointed to a beaten-down price, buyers returning, a healthy core business, an analyst Buy rating after the trial miss, and a short-term snapback as attention returned to the main drugs.
Inside the window from 2025-10-11 to 2026-01-09, HRMY reached the target in 44 days. The peak was 40.87 on 2025-12-15, with a peak gain of 54%. It ended at 38.55. The published thesis played out, and the move went past the target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.